论文部分内容阅读
美国华盛顿消息:在多伦多St Michael医院进行的一项试验表明,一种新的二氢吡啶钙拮抗剂具有强效血液动力学作用,这种作用对治疗严重心衰病人可能有益。该医院的研究人员Gordon Moe指出,这项试验证明,此新药nisoldipine为一种对心脏指数及全身血管阻力具有极度剂量相关作用的、重要的小动脉血管扩张剂。该药在结构上与广泛应用的钙阻断剂硝
Washington, DC, USA: A trial conducted at St Michael Hospital in Toronto has shown that a new calcium dihydropyridine antagonist has potent hemodynamic effects that may be of benefit in the treatment of patients with severe heart failure. Gordon Moe, a researcher at the hospital, said the trial demonstrates that the new drug, nisoldipine, is an important arteriolar vasodilator with an extremely dose-related effect on cardiac index and systemic vascular resistance. The drug is structurally related to the widely used calcium blocker nitrate